85 Artificial intelligence is rapidly becoming a key tool in the fight against cancer, offering new hope for faster, more accurate diagnoses and more personalised treatments. As cancer rates continue to rise worldwide, researchers say AI is transforming how clinicians detect and manage the disease – especially for common cancers such as breast, lung, and colorectal. The findings were published in the journal Computers in Biology and Medicine. Traditionally, diagnosing cancer has involved a combination of imaging tools and tissue biopsies. But these methods can miss early signs, are often invasive, and sometimes deliver results too late for effective intervention. Recent advances in AI, including machine learning and deep learning, are helping clinicians analyse complex medical data more quickly and precisely. These tools can scan medical images, detect patterns in genetic data, and support treatment decisions tailored to individual patients. In breast cancer, AI has already shown its ability to match or even surpass expert radiologists when analysing mammograms. Similar progress is being made in lung cancer, where deep learning systems can now identify high-risk nodules from CT scans with remarkable accuracy. For colorectal cancer, AI-assisted colonoscopy tools are helping doctors detect more polyps than before, potentially catching cancers earlier. Researchers are also exploring how AI can improve the diagnosis of blood cancers such as leukaemia and lymphoma. These conditions are often complex to detect due to subtle changes in blood cell appearance. AI systems can be trained to spot these anomalies more consistently than the human eye, offering the potential for earlier detection and improved outcomes. Another key development is the integration of AI with emerging technologies like liquid biopsy. This non-invasive technique analyses blood samples for genetic material shed by tumours. AI can enhance the interpretation of these complex data, improving screening accuracy for cancers that are otherwise difficult to detect in their early stages. Despite these breakthroughs, challenges remain. Many AI models still rely on large volumes of high-quality data to function well, which may not be available for rare cancers. There are also concerns around data privacy, algorithm transparency, and whether clinicians are ready to fully trust these systems. Ensuring robust clinical validation and regulatory oversight will be essential before AI tools can be widely adopted. Nonetheless, the potential is clear. With the ability to process genomic, proteomic, and imaging data at scale, AI is becoming indispensable to modern oncology. Experts believe the technology could eventually reduce overdiagnosis, prevent unnecessary treatments, and offer more targeted care to patients. The road ahead involves building stronger collaborations between doctors, data scientists, and engineers to ensure AI systems are both safe and effective. If these hurdles can be addressed, AI may not just support cancer care—it could reshape it entirely.
Artificial intelligence is rapidly becoming a key tool in the fight against cancer, offering new hope for faster, more accurate diagnoses and more personalised treatments. As cancer rates continue to rise worldwide, researchers say AI is transforming how clinicians detect and manage the disease – especially for common cancers such as breast, lung, and colorectal. The findings were published in the journal Computers in Biology and Medicine. Traditionally, diagnosing cancer has involved a combination of imaging tools and tissue biopsies. But these methods can miss early signs, are often invasive, and sometimes deliver results too late for effective intervention. Recent advances in AI, including machine learning and deep learning, are helping clinicians analyse complex medical data more quickly and precisely. These tools can scan medical images, detect patterns in genetic data, and support treatment decisions tailored to individual patients. In breast cancer, AI has already shown its ability to match or even surpass expert radiologists when analysing mammograms. Similar progress is being made in lung cancer, where deep learning systems can now identify high-risk nodules from CT scans with remarkable accuracy. For colorectal cancer, AI-assisted colonoscopy tools are helping doctors detect more polyps than before, potentially catching cancers earlier. Researchers are also exploring how AI can improve the diagnosis of blood cancers such as leukaemia and lymphoma. These conditions are often complex to detect due to subtle changes in blood cell appearance. AI systems can be trained to spot these anomalies more consistently than the human eye, offering the potential for earlier detection and improved outcomes. Another key development is the integration of AI with emerging technologies like liquid biopsy. This non-invasive technique analyses blood samples for genetic material shed by tumours. AI can enhance the interpretation of these complex data, improving screening accuracy for cancers that are otherwise difficult to detect in their early stages. Despite these breakthroughs, challenges remain. Many AI models still rely on large volumes of high-quality data to function well, which may not be available for rare cancers. There are also concerns around data privacy, algorithm transparency, and whether clinicians are ready to fully trust these systems. Ensuring robust clinical validation and regulatory oversight will be essential before AI tools can be widely adopted. Nonetheless, the potential is clear. With the ability to process genomic, proteomic, and imaging data at scale, AI is becoming indispensable to modern oncology. Experts believe the technology could eventually reduce overdiagnosis, prevent unnecessary treatments, and offer more targeted care to patients. The road ahead involves building stronger collaborations between doctors, data scientists, and engineers to ensure AI systems are both safe and effective. If these hurdles can be addressed, AI may not just support cancer care—it could reshape it entirely.